1 / 8

Hester Kuipers Director, Advocacy and Communications, Europe

Towards Comprehensive Prevention. Progress in the development of an AIDS vaccine. Hester Kuipers Director, Advocacy and Communications, Europe. Sharenet Amsterdam, 7 February 2013. About IAVI. To ensure the development of safe, effective, accessible,

gabe
Download Presentation

Hester Kuipers Director, Advocacy and Communications, Europe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Towards Comprehensive Prevention Progress in the development of an AIDS vaccine Hester Kuipers Director, Advocacy and Communications, Europe SharenetAmsterdam, 7 February 2013

  2. About IAVI To ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world Research portfolio of vaccine candidates Public and private-sector partners Clinical research centers in Africa Advocacy, education and outreach Epidemiology, observational, social science and policy research

  3. The potential to prevent new infections in women and girls (Modeling the Impact of an AIDS Vaccine in LMICs) No vaccine 8.8 million infections, 2020-2030 Vaccine Introduction 50% effective, 30% coverage 2.8 million (20%) infections averted 70% effective, 40% coverage 4.7 million (33%) infections averted 90% effective, 40% coverage 5.7 million (40%) infections averted

  4. AIDS vaccines hold tremendous promise

  5. Progress in Research in the AIDS vaccine field Thailand Trial shows a response for the first time in people: trial vaccine reduces HIV infection risk by 30% Powerful new antibodies discovered that block most HIV variants and that pin-point weak spots on virus Experimental vaccine approaches that can fully control virus in animal studies

  6. Looking ahead: potential vaccine candidates in efficacy testing Key programs 2012 2013 2014 2015 2015+ VRC Thailand: ALVAC (poxvirus) + Clade B/E protein* RV144 follow-on RSA: ALVAC (poxvirus) + Clade C/C protein* RSA : DNA, NYVAC + proteins/adjuvant(s)* HVTN 505: DNA prime + Ad5 boost DNA prime + Ad5 boost MHRP (& Barouch) Barouch Ad26 + MVA-CMDR+/- Env EP-DNA + IL12 + Ad35 IAVI (& Profectus) DNA prime + rTV boost (+/- protein) Chinese Govt. DNA prime + MVA Clade B boost +/- GM-CSF DNA adjuvant GeoVax Down-selected DNA +/- ChimpAd +/- MVA w/ HIV.Consv Ag Oxford Uni & IAVI DNA + protein (timing TBD) Shan Lu *BMGF invested Phase IIb or phase III / licensure trials Research track Tentative/ pending results Legend:

  7. Preventive vaccines are needed in the response to HIV/AIDS • Vaccines can make a substantial impact in reducing the number of new HIV infections • AIDS vaccines can offer value especially to women, girls, and key populations • Donors should sustain their funding for the development of vaccines and microbicideswhilst accelerating the implementation of rights-based delivery of Treatment as Prevention, VMMC and PrEP, in combination with current prevention modalities, including universal access to male and females condoms, water-based lubricants and essential education and counseling services.

More Related